Glutamatergic (Glu) synaptic inputs at phrenic motor neurons (PhMNs) predominantly comprise descending axons from respiratory centers in the ventrolateral medulla. Descending synaptic inputs provide the drive for inspiratory as well as various other behaviors that result in higher force generation. We recently examined pre‐synaptic Glu terminals (VGLUT1 and VGLUT2‐positive) around the somal membrane of PhMNs grouped according to size using a robust confocal imaging‐based technique and semi‐automated image processing, and found an ~10% higher density of Glu terminals at PhMNs in the lower tertile of somal surface area. In parallel studies, we determined the density of AMPA and NMDA mRNA expression in PhMNs grouped according to size, and found that PhMNs in the lower tertile of somal surface area display ~25% higher density of AMPA (Gria2) and NMDA (Grin1) mRNA expression compared to PhMNs in the upper tertile of somal surface area. Assuming an orderly recruitment of motor units based on their intrinsic electrophysiological properties, PhMNs in the lower tertile of somal surface area are likely recruited first in order to accomplish lower force behaviors necessary for inspiration in normoxic as well as in hypoxic (10% O 2 ) and hypercapnic (5% CO 2 ) conditions. Thus, differences in glutamatergic neurotransmission across PhMNs of increasing size support the orderly recruitment of motor units, promoting recruitment of fatigue resistant units for inspiratory behaviors. In adult male rats, unilateral C2 hemisection (C2SH) abolishes inspiratory‐related diaphragm muscle (DIAm) activity ipsilateral to injury, but DIAm activity during higher force behaviors persists, reflecting the contribution of spared inputs, likely contralateral. Accordingly, we hypothesized that C2SH primarily disrupts Glu synaptic inputs to smaller PhMNs, whereas Glu synaptic inputs to larger PhMNs are preserved. By 7 days following unilateral C2SH, there was a ~45% reduction in ipsilateral Glu synaptic input to PhMNs compared to a ~20% reduction contralaterally. Ipsilateral to C2SH, there was an ~60% reduction in presynaptic Glu terminals at PhMNs in lower tertile of somal surface area compared to ~30% reduction at PhMNs in the upper tertile of size. Contralateral to C2SH, the reduction in presynaptic Glu terminals was similar across PhMNs grouped according to somal surface area. These results are consistent with a more pronounced effect of C2SH on inspiratory behaviors of the DIAm, and the preservation of higher force behaviors after C2SH. These results also indicate that Glu synaptic input to PhMNs varies depending on motor neuron size and likely reflects different motor control, including possibly distinct central pattern generator and premotor circuits, onto PhMNs recruited for motor behaviors with varying levels of force generation. Support or Funding Information NIH Grants R01 HL96750 and HL146114
A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.
Abstract Background: Non-Hodgkin lymphoma (NHL) is a malignancy of lymphocytes, and may develop in the setting of inflammation and immune dysfunction. Small scale evaluations have suggested that common genetic variation in candidate genes related to immune function may predispose to the development of NHL. Here we report a comprehensive analysis of variants within genes associated with immunity and inflammation and risk of NHL. Methods: We used ParAllele’s Immune and Inflammation panel of 9,412 single nucleotide polymorphisms (SNPs) from 1,450 immune/inflammation genes as a discovery tool in a clinic-based study of 458 NHL cases and 484 frequency matched controls seen at the Mayo Clinic from 2002–2005. The panel included 537 coding non-synonymous SNPs (nsSNPs), with the remainder of the SNPs selected as tags from HapMap (tagSNPs) to provide coverage of the candidate genes (r2 = 0.8 and minor allele frequency >0.05). To assess the association of individual SNPs with risk of NHL, we calculated Odds Ratios (ORs) and 95% confidence intervals, adjusted for age and gender. The most prevalent homozygous genotype was used as the reference group, and each polymorphism was modeled individually as having a log-additive effect in the regression model. Associations between haplotypes from each gene and the risk of NHL were calculated using a score test implemented in HAPLO.SCORE. We also modeled the main effects for all independent (r2 <0.25) SNPs from a gene in a multivariate logistic regression model. Results: The mean age at diagnosis was 60 years for cases and 58% were male; in controls the mean age at enrollment was 61.6 years and 55% were male. In the gene analyses, the strongest findings (p≤0.001 from multiple SNP logistic regression or haplotype analysis) were for cAMP responsive element binding protein 1 (CREB1; p=0.0004), fibrinogen alpha chain (FGA; p=0.0006), TNF receptor-associated factor 1 (TRAF1; p=0.001), dual specificity phosphatase 2 (DUSP2; p=0.001), and fibrinogen gamma chain (FGG; p=0.001). In the nsSNP analyses, the strongest findings (p≤0.01) were for integrin β3 (ITGB3) L59P (OR=0.64, 0.50–0.83), Beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) H328R (OR=0.72, 0.57–0.91), transporter 2, ATP-binding cassette (TAP2) T665A (OR=1.32, 1.07–1.63), HLA-B associated transcript 2 (BAT2) V1895L (OR=0.60, 0.42–0.85), and complement component 7 (C7) T587P (OR=1.39, 1.07–1.80). Conclusions. Our results suggest that genetic variability in genes associated with antigen processing (CREB1 and TAP2), lymphocyte trafficking (B3GNT3), immune activation (TRAF1, BAT2), complement and coagulation pathways (FGA, FGG, ITGB3, C7), and MAPK signaling (DUSP2) may be important in the etiology of NHL, and should be pursued in replication studies.
Studies of the Bcl Inhibitor GX15-070 in Multiple Myeloma Demonstrate Substantial Pre-Clinical Activity.
Abstract GX15-070 is a small-molecule antagonist of the BH3-binding groove of the Bcl-2 family of proteins and can thus induce apoptosis by inhibiting the interaction between pro- and anti-apoptotic proteins. In addition, GX15-070 activates a cellular pathway, which leads to the activation of the pro-apoptotic BH3-only protein Bim, a natural cellular inhibitor of anti-apoptotic members. Together, the direct inhibition of anti-apoptotic Bcl-2 family proteins and the activation of pro-apoptotic Bim by GX15-070 can sensitize tumor cells to apoptosis. Bcl-2 family members, particularly Bcl-XL and Mcl-1 have been implicated in the survival of myeloma cells and may be responsible, in part, for drug resistance. Consequently, GX15-070 was tested against the MMRC 12 validation cell line panel, a panel of 12 standardized and annotated human myeloma cell lines (HMCLs). Western blots preformed on 8 HMCLs confirmed expression of Bcl-2, Mcl-1 and/or Bcl-XL. Basal levels of Bcl-2 and MCl-1 were relatively similar across all HMCLs studied whereas levels of Bcl-XL were variable GX15-070 inhibited the viability of all 12 myeloma cell lines as determined by MTT assay. The mean IC50 was 215 nM; range (6.4-678nM) and sensitivity did not correlate with level of Bcl-2, MCL-1 or Bcl-XL expression. On the other hand cytotoxicity to normal human blood lymphocytes, stroma and bone marrow CFUs was not observed at concentrations which were effectively cytotoxic to HMCL. Time course experiments demonstrate that apoptosis and cleavage of caspase 3 began by 12 hours and continued to increase over a 96 hour period. Co-culture with human bone marrow stroma cells (BMSCs) failed to protect HMCL from GX15-070 induced cytotoxicity. Similarly, potent MM growth factors, Interleukin 6 (IL-6) and Insulin like growth factor (IGF)-1 did not confer resistance to GX15-070. Of interest, overexpression of Bcl-2 has been shown to attenuate PS-341-induced cell death (Mitisades); however, the combination of PS-341 and GX15-070 did not reveal synergistic interaction in preliminary results. Studies looking at other drug combinations are planned. Finally, GX15-070 produced cytotoxic responses in the first primary myeloma sample tested with further testing ongoing. Mouse xenograft studies are also ongoing and will be presented. These studies indicate extensive pre-clinical activity of GX15-070 in multiple myeloma and set the stage for planned Phase II clinical trials.
Disruption of BDNF/TrkB Signaling Alters Glutamatergic mRNA Expression at Phrenic Motor Neurons
Brain‐derived neurotrophic factor (BDNF) signaling via its high affinity tropomyosin‐related kinase sub‐type B (TrkB) receptor is widely implicated in regulating glutamatergic synaptic transmission in the context of neuroplasticity. At phrenic motor neurons innervating the main inspiratory muscle in mammals (the diaphragm muscle), glutamate is the main excitatory neurotransmitter and acts primarily via ionotropic AMPA and NMDA receptors. In various regions in the CNS, BDNF/TrkB signaling influences rapid phosphorylation of AMPA and NMDA receptor subunits, supporting a main role in neuroplasticity. BDNF/TrkB signaling also plays an important role across various models of injury and respiratory neuroplasticity. In addition, BDNF/TrkB signaling increases AMPA and NMDA receptor expression in the CNS, but whether this effect is also present in motor neurons is presently unknown. BDNF/TrkB signaling modulates motor neuron excitability, which may reflect changes in glutamatergic receptor expression. In the present study, AMPA and NMDA mRNA expression in retrogradely‐labeled phrenic motor neurons was measured using RNAscope in situ hybridization (ACDBio). Adult male rats were randomly assigned to control (untreated) and 11‐day treatment groups (12 ml/day) with intrathecal infusion of the fusion‐protein TrkB‐Fc or artificial cerebrospinal fluid (aCSF) in the region of the phrenic motor neuron pool. Intrathecal catheter tip position was verified at the terminal experimental at ~C4 segment, and the infusion rate was confirmed to restrict delivery to the cervical spinal cord. Expression of both AMPA and NMDA receptor mRNA was evident as puncta in phrenic motor neurons (identified by cholera toxin sub‐unit B – CTB‐labeling) as well as in other large neurons in the ventral horn. Our analysis of mRNA puncta density was restricted to clearly‐identified, retrogradely (CTB)‐labeled phrenic motor neurons containing the mid‐nuclear region in frozen, thin (10μm) longitudinal sections of the spinal cord. At least 25 phrenic motor neurons were stereologically selected for analysis in each animal. No differences in AMPA or NMDA mRNA density were evident between the untreated control and aCSF treated groups, and these results were combined. Across phrenic motor neurons in the control and aCSF groups, there was ~30% variance in AMPA and NMDA mRNA density within each animal, reflecting heterogeneity across motor neurons of varying size, expected to be recruited for the various levels of force production by the diaphragm muscle. Following TrkB‐Fc infusion, there was evidence of decreased AMPA mRNA density in phrenic motor neurons following but no change in NMDA mRNA density. These results support a role for BDNF/TrkB signaling in modulating glutamatergic receptor expression at phrenic motor neurons, which may thus contribute to the regulation of motor neuron excitability and neuroplasticity following injury or disease. Support or Funding Information NIH grants R01 HL96750 and R01 HL146114
Genetic Disruption of the SH3 and SAM Domains of HACS1 Enhances Adaptive Immunity.
Abstract HACS1 is a SH3 (Src homology 3) and SAM (sterile alpha motif) domain containing adaptor protein that is expressed in activated B and dendritic cells, is up-regulated by Interleukin 4 in the process of B cell activation and likely serves to dampen the immune response. To elucidate the function of HACS1, we generated HACS1 gene knockout mice by deletion of the SH3 and SAM domains. HACS1−/− mice were viable and fertile and had normal bone marrow B cell development and normal splenic T and B cell populations. However, adult HACS1−/− mice had increased numbers of peritoneal B1 cells (IgM+CD5+). Upon LPS plus BCR or TCR stimulations, splenic cells from HACS1−/− mice demonstrated an upregulation of activation markers with increased intensity of CD23 expression or increased population of CD69 positive cells. Purified B220+ splenic B cells from HACS1−/− mice showed increased cell proliferation upon BCR stimulation. Both T helper type 1 (Th1) and T helper type 2 (Th2) humoral responses were enhanced in HACS1−/− mice upon immunization with T cell-dependent antigen NP-KLH, which resulted in increased production of interferon-gamma (IFN-γ), anti-NP IgG2a and IL-4, as well as anti-NP IgG1 and IgE. Upon immunization with T cell-independent antigens such as TNP-LPS and TNP-Ficoll, HACS1−/− mice had increased production of anti-TNP IgM and IgG3 as compared to normal controls. The in vitro maturation of bone marrow-derived dentritic cells from HACS1−/− mice was similar to wild-type mice but HACS1−/− dentritic cells showed increased IL-12 production upon stimulation with anti-CD40 or LPS. There was no significant difference in antigen uptake by cultured dentritic cells from non-immunized wild-type or knockout mice. However, in immunized mice, an increase in antigen uptake in HACS1−/− dentritic cells was observed. We further demonstrate that the HACS1−/− B cells had increased tyrosine phosphorylation in the resting state. As deletion of the SH3 & SAM domains of HACS1 appears to generate a hypersensitive immune response, our results collectively support that HACS1 negatively regulates adaptive immunity.
Phrenic motoneuron expression of neurotrophins and their receptor TrkB following cervical C2 spinal cord hemisection
In previous studies, we found that after cervical spinal cord hemisection at C2 (SH), neuromuscular transmission improved in the rat diaphragm muscle (DIAm). We also found that exogenous brain‐derived neurotrophic factor (BDNF) treatment enhanced neuromuscular transmission, whereas inhibiting activation of its receptor (TrkB) worsened neuromuscular transmission. We hypothesized that expression of BDNF and/or its receptor TrkB at phrenic motoneurons would increase following SH. In the present study, adult male rats underwent SH or sham surgery. Phrenic motoneurons were labeled by injection of cholera toxin B into the DIAm and retrogradely‐labeled phrenic motoneurons were sampled by laser capture microdissection (LCM). BDNF and TrkB receptor (truncated – T1 and full length – FL) mRNA were measured in LCM‐microdissected motoneurons using quantitative real‐time RT‐PCR and expressed as a ratio to ribosomal S16 RNA. We found that BDNF mRNA expression in phrenic motoneurons increased by 3 days after SH (~2‐fold). Similarly, both TrkB.T1 and TrkB.FL mRNA increased by 3 days after SH (~17‐ and ~11‐fold, respectively). It is possible that the relative expression of neurotrophins and their receptors (truncated or full‐length) may determine the time‐course of restoration of phrenic activity following SH. Supported by NIH grants AR51173 and HL37680 and the Mayo Foundation.
Recruitment order of diaphragm muscle (DIAm) motor units is maintained with the restoration of rhythmic DIAm activity following cervical C2 spinal cord hemisection
DIAm motor units are normally recruited in an orderly fashion to accomplish different ventilatory and non‐ventilatory behaviors. Following a cervical spinal cord hemisection at C2 (SH), there is restoration of phrenic activity over time. We hypothesized that an orderly recruitment of DIAm motor units is maintained with the restoration of rhythmic DIAm electromyographic (EMG) activity following SH. A pair of electrode wires was implanted into the midcostal regions of the DIAm of adult male rats for chronic EMG recording. Three days later, these animals underwent SH surgery. We examined changes in integrated DIAm EMG activity across different motor behaviors (i.e., eupnea, hypercapnia, tracheal occlusion and fictive sneezing) assuming that DIAm EMG activity during fictive sneezing represents the maximum recruitment of DIAm motor units. As expected in controls, DIAm EMG activity increased from eupnea (~27% of max) to hypercapnia (5% CO 2; ~45% of max) to sustained tracheal occlusion (~60% of max). By 14 days after SH with restored rhythmic DIAm activity, the amplitude of EMG activity on the ipsilateral side was reduced, and the changes in EMG activity induced by increased ventilatory and non‐ventilatory drive were blunted, although an orderly recruitment of motor units was still observed. These results support a generalized strengthening of contralateral presynaptic drive over time following spinal cord injury. Supported by NIH grants AR51173 and HL37680 and the Mayo Foundation.
Detection of TDP‐43 in Alzheimer's disease and hippocampal sclerosis
Frontotemporal lobar degeneration with ubiquitin immunoreactive inclusions (FTLD‐U) is the most common cause of frontal lobe dementia. Recently, the TAR DNA binding protein (TDP‐43) has been described as a marker for FTLD‐U. TDP‐43 has been reported to be specific for neuronal inclusions in FTLD‐U and not other degenerative disorders such as Alzheimer's disease (AD). The reported specificity of TDP‐43 makes it possible to detect FTLD‐U in the setting of other neurodegenerative diseases. On this assumption, we determined the frequency of FTLD‐U in AD. Additionally, since FTLD‐U is often associated with hippocampal sclerosis (HpScl), a process characterized by neuronal loss in Sommer's sector of the hippocampus, we also determined the frequency of FTLD‐U in HpScl. A series of 74 AD and 20 HpScl cases were screened with TDP‐43 immunohistochemistry. Immunoreactivity for TDP‐43 was detected in 13 of 20 (65%) HpScl cases and 42 of 74 (57%) AD cases, including 33 of 44 (75%) cases of AD with HpScl and 9 of 30 (30%) cases of AD without HpScl. The specificity of TDP‐43 was assessed by double immunolabeling for tau at the light and electron microscopic level. The frequency of tau and TDP‐43 co‐localization was 13%. At the EM level TDP‐43 immunoreactivity was present in cytosolic granular material, but some tau‐positive filaments were also labeled. The results suggest that FTLD‐U occurs frequently in HpScl and AD.
Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery
ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1